Phase III
It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.
85% of participants in the trial of Actemra were from minority racial and ethnic groups, which are historically underrepresented in clinical studies.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 16, 2020.
Shares of Marinus Pharmaceuticals soared more than 60% in after-hours trading Monday following the company’s announcement that its experimental epilepsy treatment ganaxolone hit the mark in a Phase III study.
AstraZeneca resumed its vaccine testing in the United Kingdom following confirmation from the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 14, 2020.
Eli Lilly and Company announced today that it has seen positive results from CENTURION, its Phase III study looking into Reyvow (lasmiditan) for migraine attacks.
It was a busy week for clinical trial updates. Here’s a look.
Based on the positive results of Trikafta, the company plans to submit sNDA to the FDA in the fourth quarter and other regulatory agencies around the world afterward.
PRESS RELEASES